Tags

Type your tag names separated by a space and hit enter

Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model.
Carcinogenesis. 2008 Nov; 29(11):2182-9.C

Abstract

Aberrant arachidonic acid metabolism, especially altered cyclooxygenase and 5-lipoxygenase (LOX) activities, has been associated with chronic inflammation as well as carcinogenesis in human oral cavity tissues. Here, we examined the effect of Zyflamend, a product containing 10 concentrated herbal extracts, on development of 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced inflammation and oral squamous cell carcinoma (SCC). A hamster cheek pouch model was used in which 0.5% DMBA was applied topically onto the left cheek pouch of male Syrian golden hamsters either three times per week for 3 weeks (short term) or 6 weeks (long term). Zyflamend was then applied topically at one of three different doses (25, 50 and 100 microl) onto the left cheek pouch three times for 1 week (short-term study) or chronically for 18 weeks. Zyflamend significantly reduced infiltration of inflammatory cells, incidence of hyperplasia and dysplastic lesions, bromodeoxyuridine-labeling index as well as number of SCC in a concentration-dependent manner. Application of Zyflamend (100 microl) reduced formation of leukotriene B(4) (LTB(4)) by 50% compared with DMBA-treated tissues. The reduction of LTB(4) was concentration dependent. The effect of Zyflamend on inhibition of LTB(4) formation was further confirmed with in vitro cell-based assay. Adding LTB(4) to RBL-1 cells, a rat leukemia cell line expressing high levels of 5-LOX and LTA(4) hydrolase, partially blocked antiproliferative effect of Zyflamend. This study demonstrates that Zyflamend inhibited LTB(4) formation and modulated adverse histopathological changes in the DMBA-induced hamster cheek pouch model. The study suggests that Zyflamend might prevent oral carcinogenesis at the post-initiation stage.

Authors+Show Affiliations

Department of Experimental Therapeutics The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18687669

Citation

Yang, Peiying, et al. "Zyflamend Reduces LTB4 Formation and Prevents Oral Carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced Hamster Cheek Pouch Model." Carcinogenesis, vol. 29, no. 11, 2008, pp. 2182-9.
Yang P, Sun Z, Chan D, et al. Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model. Carcinogenesis. 2008;29(11):2182-9.
Yang, P., Sun, Z., Chan, D., Cartwright, C. A., Vijjeswarapu, M., Ding, J., Chen, X., & Newman, R. A. (2008). Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model. Carcinogenesis, 29(11), 2182-9. https://doi.org/10.1093/carcin/bgn181
Yang P, et al. Zyflamend Reduces LTB4 Formation and Prevents Oral Carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced Hamster Cheek Pouch Model. Carcinogenesis. 2008;29(11):2182-9. PubMed PMID: 18687669.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model. AU - Yang,Peiying, AU - Sun,Zheng, AU - Chan,Diana, AU - Cartwright,Carrie A, AU - Vijjeswarapu,Mary, AU - Ding,Jibin, AU - Chen,Xiaoxin, AU - Newman,Robert A, Y1 - 2008/08/06/ PY - 2008/8/9/pubmed PY - 2008/12/17/medline PY - 2008/8/9/entrez SP - 2182 EP - 9 JF - Carcinogenesis JO - Carcinogenesis VL - 29 IS - 11 N2 - Aberrant arachidonic acid metabolism, especially altered cyclooxygenase and 5-lipoxygenase (LOX) activities, has been associated with chronic inflammation as well as carcinogenesis in human oral cavity tissues. Here, we examined the effect of Zyflamend, a product containing 10 concentrated herbal extracts, on development of 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced inflammation and oral squamous cell carcinoma (SCC). A hamster cheek pouch model was used in which 0.5% DMBA was applied topically onto the left cheek pouch of male Syrian golden hamsters either three times per week for 3 weeks (short term) or 6 weeks (long term). Zyflamend was then applied topically at one of three different doses (25, 50 and 100 microl) onto the left cheek pouch three times for 1 week (short-term study) or chronically for 18 weeks. Zyflamend significantly reduced infiltration of inflammatory cells, incidence of hyperplasia and dysplastic lesions, bromodeoxyuridine-labeling index as well as number of SCC in a concentration-dependent manner. Application of Zyflamend (100 microl) reduced formation of leukotriene B(4) (LTB(4)) by 50% compared with DMBA-treated tissues. The reduction of LTB(4) was concentration dependent. The effect of Zyflamend on inhibition of LTB(4) formation was further confirmed with in vitro cell-based assay. Adding LTB(4) to RBL-1 cells, a rat leukemia cell line expressing high levels of 5-LOX and LTA(4) hydrolase, partially blocked antiproliferative effect of Zyflamend. This study demonstrates that Zyflamend inhibited LTB(4) formation and modulated adverse histopathological changes in the DMBA-induced hamster cheek pouch model. The study suggests that Zyflamend might prevent oral carcinogenesis at the post-initiation stage. SN - 1460-2180 UR - https://www.unboundmedicine.com/medline/citation/18687669/Zyflamend_reduces_LTB4_formation_and_prevents_oral_carcinogenesis_in_a_712_dimethylbenz[alpha]anthracene__DMBA__induced_hamster_cheek_pouch_model_ L2 - https://academic.oup.com/carcin/article-lookup/doi/10.1093/carcin/bgn181 DB - PRIME DP - Unbound Medicine ER -